Receipt of PARP Inhibitors in Patients With Metastatic Prostate Cancer Harboring Alterations

How often are poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors used in patients with metastatic castration–resistant prostate cancer (mCRPC) harboring alterations?In this cohort study of 443 patients with mCRPC and alterations, 51.2% received a PARP inhibitor, whereas 48.8% did not. Patients with Medicare insurance had higher odds of receiving a PARP inhibitor.These findings suggest that despite the availability of biomarker-selected life-prolonging therapies, a sizeable number of patients with mCRPC and alterations do not receive PARP inhibitors, highlighting the need to improve awareness of the data and access to these agents.

Corresponding Authors: Neeraj Agarwal, MD (neeraj.agarwal@hci.utah.edu), and Umang Swami, MD, MS (umang.swami@hci.utah.edu), Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, 2000 Circle of Hope Dr, Ste 5510, Salt Lake City, UT 84112.

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.